#Japan #Yokohama #Stemchymal #REPROCELL #SCA

REPROCELL Seeks Regulatory Approval for Stemchymal®

On June 24, 2026, REPROCELL Inc. announced a significant milestone in its journey toward advancing regenerative medicine. The company has officially submitted a manufacturing and marketing authorization request in Japan for Stemchymal®, its stem cell-based treatment tailored for patients suffering from spinocerebellar ataxia type 3 (SCA3) and type 6 (SCA6).

Spinocerebellar ataxia is a degenerative neurological condition that leads to a progressive loss of motor functions, placing immense challenges on those affected. Currently, there are limited effective treatment options available, highlighting the urgent need for new therapies. Stemchymal® aims to address this critical medical requirement by potentially slowing disease progression and enhancing patients' quality of life.

Under a partnership agreement, Stemchymal® will be manufactured by Steminent Biotherapeutics Inc. based in Taiwan, while REPROCELL will oversee all sales and distribution activities within Japan. Notably, Stemchymal® was designated as an orphan regenerative medicine product by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in December 2018. This recognition allows for expedited review processes through the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, targeting a regulatory review timeframe of approximately nine months following application acceptance.

Chikafumi Yokoyama, CEO of REPROCELL, expressed his enthusiasm regarding the submission, stating, "We are thrilled to announce the filing for marketing authorization for Stemchymal® in the treatment of spinocerebellar ataxia (SCA3 and SCA6). With current treatments being limited and this disease regarded as incurable, we see a significant medical need for innovative therapeutic options. We firmly believe that Stemchymal® could play a pivotal role in alleviating symptoms and improving quality of life for patients suffering from this condition. Our organization is committed to obtaining market approval as promptly as possible to provide this revolutionary treatment to those in need."

Financial Implications

Although REPROCELL anticipates that this regulatory filing will have a minimal immediate impact on the company's consolidated financial results for the fiscal year ending March 31, 2027, they view this submission as a potential catalyst for medium to long-term growth and enhanced corporate value. The company remains dedicated to communicating any significant developments as they occur, signaling their commitment to transparency and ongoing engagement with stakeholders.

The need for innovative approaches like Stemchymal® underscores a broader significance in the realm of regenerative medicine, particularly in addressing unmet medical needs and enhancing patient care in previously challenging conditions such as spinocerebellar ataxia. As REPROCELL progresses through the regulatory landscape, there lies a hopeful horizon for both the company and the patients who may benefit from this groundbreaking treatment.